脂质奈米颗粒原料市场- 副产品（试剂盒[可电离、聚乙二醇化和甾醇脂质]试剂）、应用（治疗、研究）、适应症（癌症、传染病、血液疾病）、最终用途- 全球预测（2024 - 2032） ）

在製药和生物技术领域不断扩大的应用的推动下，脂质奈米颗粒原料市场规模预计在 2024 年至 2032 年间复合年增长率为 5.7%。脂质奈米粒子 (LNP) 作为 mRNA 疫苗的有效递送系统而受到广泛关注。这导致该技术在其他治疗领域的投资和研究增加，包括基因治疗、癌症治疗和罕见疾病。

对个人化医疗和精准治疗的兴趣日益浓厚也将影响市场的成长。 LNP 提供了一个多功能平台，可提供具有客製化特性的各种治疗方法，使其成为客製化治疗方案的理想选择。慢性病的日益普及和对创新治疗解决方案的需求刺激了对脂质为基础的药物传递系统的研究。根据世界卫生组织的数据，慢性病每年导致 4,100 万人死亡，占全球死亡人数的 74%。不断增加的政府资金和支持性监管框架也鼓励创新并确保高品质原料的供应，从而促进市场成长。

整个产业分为产品、适应症、应用、最终用途和地区。

从产品来看，由于脂质奈米颗粒的合成和配方，试剂领域的脂质奈米颗粒原料市场预计到 2032 年将大幅成长。脂质、溶剂和稳定剂等试剂对于製备具有精确特性的 LNP 至关重要，以适应有效的药物传递。用于各种治疗应用（包括 mRNA 疫苗和基因疗法）的 LNP 配方的复杂性和特异性日益增加，也将推动对高品质、可靠试剂的需求。

由于奈米技术和药物传输系统的不断进步和创新，研究领域的脂质奈米颗粒原料市场预计到 2032 年将录得可观的成长率。深入的研究工作集中在优化脂质奈米颗粒的特性和功能，用于各种治疗应用，包括标靶药物传递、基因治疗和疫苗开发。

由于製药和生物技术产业的不断扩大，以及政府对医疗保健基础设施和研究投资的支持，预计亚太地区脂质奈米颗粒原料产业规模将在 2024 年至 2032 年期间大幅成长。大量熟练的研究人员和科学家的存在，加上具有成本效益的製造能力，正在加强亚太地区脂质奈米颗粒技术的开发和生产。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 慢性病盛行率增加
    • 药物传输技术的进步
    • 政府支持和资助
    • 生医产业快速扩张
  • 产业陷阱与挑战
    • 严格的监管场景
    • 开发成本高
• 成长潜力分析
• 技术景观
• 监管环境
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司市占率分析
• 竞争定位矩阵
• 战略展望矩阵

第 5 章：市场估计与预测：按产品分类，2021 - 2032 年

• 主要趋势
• 套件
  • 可电离脂质
  • 聚乙二醇化脂质
  • 固醇脂质
  • 中性磷脂
• 试剂
• 其他产品

第 6 章：市场估计与预测：按应用分类，2021 - 2032

• 主要趋势
• 疗法
• 研究

第 7 章：市场估计与预测：按指标划分，2021 - 2032 年

• 主要趋势
• 癌症
• 传染性疾病
• 血液疾病
• 其他适应症

第 8 章：市场估计与预测：按最终用途，2021 - 2032 年

• 主要趋势
• 製药和生物技术公司
• 学术及研究机构
• 其他最终用户

第 9 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 荷兰
  • 义大利
  • 欧洲其他地区
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 沙乌地阿拉伯
  • 南非
  • 阿联酋
  • 中东和非洲其他地区

第 10 章：公司简介

• Biopharma PEG Scientific Inc.
• BroadPharm
• CordenPharma
• Creative Biolabs.
• Croda International Plc
• Echelon Biosciences
• Merck KGaA
• NOF Corporation
• Polysciences, Inc.
• Tebubio

Lipid nanoparticle raw materials market size is estimated to register 5.7% CAGR between 2024 and 2032, driven by expanding applications in pharmaceutical and biotechnology sectors. Lipid nanoparticles (LNPs) have gained significant attention as effective delivery systems for mRNA vaccines. This has led to increased investments and research in this technology for other therapeutic areas, including gene therapy, cancer treatment, and rare diseases.

The rising interest in personalized medicine and precision therapeutics will also influence the market growth. LNPs offer a versatile platform for delivering a wide range of therapeutics with tailored properties, making them ideal for customized treatment regimens. The increasing prevalence of chronic diseases and the need for innovative treatment solutions have spurred research into lipid-based drug delivery systems. As per WHO, chronic diseases cause 41 million deaths annually, accounting for 74% of all global fatalities. The rising government funding and supportive regulatory frameworks are also encouraging innovations and ensuring the availability of high-quality raw materials, adding to the market growth.

The overall industry is classified into product, indication, application, end-use and region.

Based on product, the lipid nanoparticle raw materials market from the reagents segment is predicted to witness substantial growth rate through 2032 due to the synthesis and formulation of lipid nanoparticles. Reagents, such as lipids, solvents, and stabilizers are essential for creating LNPs with precise characteristics to cater to effective drug delivery. The increasing complexity and specificity of LNP formulations for various therapeutic applications, including mRNA vaccines and gene therapies, will also drive the demand for high-quality, reliable reagents.

Lipid nanoparticle raw materials market from the research segment is predicted to record decent growth rate through 2032, owing to the continuous advancements and innovations in nanotechnology and drug delivery systems. Intensive research efforts are focused on optimizing the properties and functionalities of lipid nanoparticles for various therapeutic applications, including targeted drug delivery, gene therapy, and vaccine development.

Asia Pacific lipid nanoparticles raw materials industry size is anticipated to grow at a significant pace over 2024-2032 attributed to the expanding pharmaceutical and biotechnology industries, supported by government investments in healthcare infrastructure and research. The presence of a large pool of skilled researchers and scientists, coupled with cost-effective manufacturing capabilities, is enhancing the development and production of lipid nanoparticle technologies in APAC.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of chronic diseases
    • 3.2.1.2 Advancements in drug delivery technologies
    • 3.2.1.3 Government support and funding
    • 3.2.1.4 Rapid expansion of the biopharmaceutical industry
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Stringent regulatory scenario
    • 3.2.2.2 High development costs
• 3.3 Growth potential analysis
• 3.4 Technological landscape
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive positioning matrix
• 4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Kits
  • 5.2.1 Ionizable lipids
  • 5.2.2 PEGylated lipids
  • 5.2.3 Sterol lipids
  • 5.2.4 Neutral phospholipids
• 5.3 Reagents
• 5.4 Other products

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Therapeutics
• 6.3 Research

Chapter 7 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Cancer
• 7.3 Infectious diseases
• 7.4 Blood diseases
• 7.5 Other indications

Chapter 8 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Pharmaceutical & biotechnology companies
• 8.3 Academic & research institutes
• 8.4 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Netherlands
  • 9.3.6 Italy
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 South Africa
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Biopharma PEG Scientific Inc.
• 10.2 BroadPharm
• 10.3 CordenPharma
• 10.4 Creative Biolabs.
• 10.5 Croda International Plc
• 10.6 Echelon Biosciences
• 10.7 Merck KGaA
• 10.8 NOF Corporation
• 10.9 Polysciences, Inc.
• 10.10 Tebubio